Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSPERO long-term extension study of tozorakimab in COPD with exacerbation history
MOH_2023-05-31_012690Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tozorakimab in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Severe COPD exacerbations. Started Apr 2023; status: completed.
02
Drugs
tozorakimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on MOH_2023-05-31_012690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-05-31_012690.